PhRMA Unveils a Three-Point Plan to Address Trump Concerns About Drug Prices and Manufacturing

There’s a lot to go through this morning. Let’s get at it. I’m thinking about rare diseases this morning for a couple of reasons.  First, there is this JAMA Internal

My goodness. 2024 already. For a lot of us, that means a scramble to get situated before the J.P. Morgan Healthcare conference begins this weekend. If you’re headed to SF,

There’s a long Arc today on a detailed IRA-related argument that deserves a (more) detailed response. At least, it’s long by my standards (650 words), and I feel it’s fair